The Global Electroconvulsive Therapy Devices Market, in terms of revenue, was estimated to be USD 14.96 Million in 2020 and is expected to reach USD 16.20 Million in 2025, growing at a CAGR of 2.09% from 2019 to 2025.
ECT is treatment considered as most safe and effective for certain psychiatric illnesses. ECT is the most common treatment executed for severe or major type of depression. Though, the mechanism of action for this treatment is not fully known.
Key players in the market consist of Mecta, Ectron, I.E. Somatic, St.Jude Medical, Others
MECTA is on the cutting edge of ECT technology and patient safety. ECT continues to be the only neuromodulator modality providing up to an 80% response rate. We are proud that MECTA's innovative device designs have been utilized worldwide in peer reviewed randomized, double-blind studies. MECTA recently reported on the safety and feasibility of this new form of ECT (FEAST) in a cohort of depressed patients (n = 17) who were free of antidepressant medication.9 during the conduct of that study, the FEAST methods were refined. Changes were made to the size of the electrodes, with the initial electrodes consisting of a circular anterior electrode with a diameter of 0.75 inch and an oblong posterior electrode.
Ectron Corporation announced on July 2020- it has joined Microsoft Azure Certified for Internet of Things (IoT), ensuring customers get IoT solutions up and running quickly with hardware and software that has been pre-tested and verified to work with Microsoft Azure IoT services. Microsoft Azure Certified for IoT allows businesses to reach customers where they are, working with an ecosystem of devices and platforms, allowing for faster time to production.
ECT is approved by the U.S. Food and Drug Administration (FDA) and has been shown to be highly effective, giving some patients full reversal of severe depression symptoms. Overall, ECT is approximately 80 percent effective when a patient is a good candidate. By comparison, about 50 percent of patients respond to antidepressant medication.
Sept 2020-New research of Dr. Giulio Brancati, a resident in clinical and experimental medicine at the University of Pisa out of Italy suggests that reputation may be unwarranted. Investigators found that among bipolar patients who fail to respond to standard treatments, ECT can be a lifesaver, preventing out-of-control mood swings and dramatically lowering suicide risk. The study tracked 670 Italian adults who had ECT for bipolar disorder at a single psychiatric clinic between 2006 and 2019. Importantly, 84% of patients showing high risk of suicide before ECT were no longer considered overtly suicidal after treatment.
Global electroconvulsive therapy devices market has been segmented based on Product type, Unilateral and Bilateral. Based on end user, global electroconvulsive therapy therapeutics market has been segmented as Hospitals, Specialty Clinics, Mental Hospitals and Others. Global electroconvulsive therapy device market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the global electroconvulsive therapy device market for due to high prevalence of mental disorders. North America held the largest market share acquired in 2019. In North America the United States is one and the major revenue contributing countries will always have a special role in the global market. High prevalence of mental disorders is one of the key growth factor in this region Europe is expected to hold second largest market share in global electroconvulsive therapy device market.